Catalent unveils new formulation service; Icon mounts a share buyback;

> Catalent ($CTLT) has introduced OptiPact, a new formulation offering that taps the company's roller compaction technology for drug manufacturing. More

> Icon ($ICON) wrapped up a $40 million share buyback, clearing the way to acquire $100 million more as it looks to optimize its capital structure. News

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.